Vertebrobasilar Artery Syndrome Treatment Market Outlook:
Vertebrobasilar Artery Syndrome Treatment Market size was over USD 48.63 billion in 2025 and is projected to reach USD 60.45 billion by 2035, witnessing around 2.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of vertebrobasilar artery syndrome treatment is assessed at USD 49.59 billion.
The primary factor for the global market is the rising cases of vertebrobasilar insufficiency among the global population owing to the increasing number of diseases and illnesses. The increasing cases of vertebrobasilar insufficiency are generating the need for vertebrobasilar artery syndrome treatment and helping in the expansion of the market size. According to the recent statistics conducted by researchers in 2021, it was found that the prevalence of vertebrobasilar arteries was prevalent in 21% of the elderly worldwide. Furthermore, the mortality rate of vertebrobasilar insufficiency falls under 75% - 85%.
Vertebrobasilar artery syndrome is a medical condition that has increased in the past few years. In this condition, there is a temporary decrease in blood flow in the posterior circulation of the brain. The blockage of basilar arteries occurs over time through a process called atherosclerosis, or the build-up of plaque. The most common symptoms are vertigo, dizziness, headaches, vomiting, ataxia, and weakness in the body. Furthermore, the vertebrobasilar artery could also lead to arterial hypertension, obesity, and smoking. The main factors for the expansion of the global vertebrobasilar artery syndrome market are the rising prevalence of artery disorders, lifestyle illnesses, and other genetic problems.
